系统综述与Meta分析:大环内酯类药物治疗内镜鼻窦手术后慢性鼻窦炎
本系统综述与Meta分析纳入8项随机对照试验共606例长期使用大环内酯类药物的慢性鼻窦炎内镜术后患者,结果显示大环内酯类药物与安慰剂在SNOT评分(SMD=-0.13,95%CI -0.38至0.13,I²=0%)和VAS评分(SMD=-0.10,95%CI -0.88至0.68,I²=81%)上无显著差异,但在改善鼻内镜评分(NES)方面优于安慰剂(SMD=-0.32,95%CI -0.62至-0.03,I²=21%),且未增加不良事件发生率。
要点
- 长期使用大环内酯类药物可能不会显著改善慢性鼻窦炎术后患者的生活质量和疾病严重程度。
- 大环内酯类药物可能对改善慢性鼻窦炎术后鼻内镜评分(NES)有作用。
- 大环内酯类药物的使用未增加不良事件的发生率。
核心结论
- 慢性鼻窦炎术后长期使用大环内酯类药物可能不会显著改善患者的生活质量和疾病严重程度,但可能对改善术后鼻内镜评分(NES)有作用。
- 目前仍无足够证据确定慢性鼻窦炎的疾病表型或患者种族是否会影响术后长期使用大环内酯类药物的疗效。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Web of Science、Embase和Cochrane Library数据库,检索日期为2022年6月2日,纳入关于大环内酯类抗生素治疗慢性鼻窦炎内镜手术患者的随机对照试验。
- 共纳入8项研究,涉及606例长期使用大环内酯类药物的患者。
主要发现
- 大环内酯类药物组与安慰剂组在SNOT评分上无显著差异(SMD=-0.13;95%CI -0.38至0.13,I²=0%)。
- 大环内酯类药物组与安慰剂组在VAS评分上无显著差异(SMD=-0.10;95%CI -0.88至0.68,I²=81%)。
- 大环内酯类药物组在改善NES方面优于安慰剂组(SMD=-0.32;95%CI -0.62至-0.03,I²=21%)。
- 使用大环内酯类药物未增加不良事件的发生率。
关键数值与推荐
- 主要结局指标为鼻窦炎结局测试(SNOT)评分和视觉模拟量表(VAS)评分。
- 次要结局指标为鼻内镜评分(NES)、鼻窦计算机断层扫描评分和不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the efficacy and safety of macrolide antibiotics therapy in patients with chronic rhinosinusitis (CRS) receiving endoscopic sinus surgery. DATA SOURCES: PubMed, Web of Science, Embase, and Cochrane Library. REVIEW METHODS: The electronic databases were comprehensively searched on June 2, 2022, for randomized controlled trials on macrolide antibiotics in the treatment of patients undergoing CRS endoscopic surgery. The primary outcome measures were the sinonasal outcome test (SNOT) score and the visual analog scale (VAS) score. The secondary outcome measures were the nasal endoscopy score (NES), the sinus computed tomography score, and adverse events. RESULTS: A total of 8 studies were included, involving 606 patients who used macrolide for a long time. Meta-analysis showed that no significant difference was observed in SNOT (standardized mean difference [SMD] = -0.13; 95% confidence interval [CI]: -0.38 to 0.13, I2 = 0%) and VAS (SMD = -0.10; 95% CI, -0.88 to 0.68, I2 = 81%) between the macrolide and placebo groups. However, macrolide outperformed the placebo in improving NES (SMD = -0.32; 95% CI, -0.62 to -0.03, I2 = 21%). The use of macrolide did not increase the incidence of adverse events. CONCLUSION: Long-term use of macrolide after CRS surgery may not significantly improve the quality of life and disease severity of the patients but may play a role in improving postoperative NES in patients with CRS. There is still no sufficient evidence to determine whether the disease phenotype of CRS or the patient's race will affect the efficacy of long-term use of macrolide after CRS.
引用
- Shu F, Li CX, Zhang F, et al. Systematic Review and Meta-analysis: Macrolide in the Treatment of Chronic Rhinosinusitis After Endoscopic Sinus Surgery. Otolaryngol Head Neck Surg. 2023. PMID: 37548067. doi:10.1002/ohn.461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。